WO2005042695A3 - Lipoparticles comprising proteins, methods of making, and using the same - Google Patents

Lipoparticles comprising proteins, methods of making, and using the same Download PDF

Info

Publication number
WO2005042695A3
WO2005042695A3 PCT/US2004/024984 US2004024984W WO2005042695A3 WO 2005042695 A3 WO2005042695 A3 WO 2005042695A3 US 2004024984 W US2004024984 W US 2004024984W WO 2005042695 A3 WO2005042695 A3 WO 2005042695A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoparticles
methods
proteins
making
same
Prior art date
Application number
PCT/US2004/024984
Other languages
French (fr)
Other versions
WO2005042695A2 (en
Inventor
Benjamin J Doranz
Sharon Willis
Eric D Ross
Tiffani Anne Greene
Original Assignee
Integral Molecular Inc
Benjamin J Doranz
Sharon Willis
Eric D Ross
Tiffani Anne Greene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Molecular Inc, Benjamin J Doranz, Sharon Willis, Eric D Ross, Tiffani Anne Greene filed Critical Integral Molecular Inc
Priority to AU2004286197A priority Critical patent/AU2004286197A1/en
Priority to CA002534236A priority patent/CA2534236A1/en
Priority to EP04816792.8A priority patent/EP1660638B1/en
Publication of WO2005042695A2 publication Critical patent/WO2005042695A2/en
Publication of WO2005042695A3 publication Critical patent/WO2005042695A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention relates to lipoparticles. The invention also relates to producing lipoparticles. The invention further relates to lipoparticles comprising a viral structural protein. The invention further relates to a lipoparticle comprising a membrane protein, and the lipoparticle can be attached to a sensor surface. The invention further relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.
PCT/US2004/024984 2003-07-30 2004-07-30 Lipoparticles comprising proteins, methods of making, and using the same WO2005042695A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2004286197A AU2004286197A1 (en) 2003-07-30 2004-07-30 Lipoparticles comprising proteins, methods of making, and using the same
CA002534236A CA2534236A1 (en) 2003-07-30 2004-07-30 Lipoparticles comprising proteins, methods of making, and using the same
EP04816792.8A EP1660638B1 (en) 2003-07-30 2004-07-30 Lipoparticles comprising proteins, methods of making, and using the same

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US49163303P 2003-07-30 2003-07-30
US49147703P 2003-07-30 2003-07-30
US60/491,633 2003-07-30
US60/491,477 2003-07-30
US49875503P 2003-08-29 2003-08-29
US60/498,755 2003-08-29
US50247803P 2003-09-12 2003-09-12
US60/502,478 2003-09-12
US50957503P 2003-10-07 2003-10-07
US50967703P 2003-10-07 2003-10-07
US50960803P 2003-10-07 2003-10-07
US60/509,608 2003-10-07
US60/509,677 2003-10-07
US60/509,575 2003-10-07

Publications (2)

Publication Number Publication Date
WO2005042695A2 WO2005042695A2 (en) 2005-05-12
WO2005042695A3 true WO2005042695A3 (en) 2007-01-18

Family

ID=34557921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024984 WO2005042695A2 (en) 2003-07-30 2004-07-30 Lipoparticles comprising proteins, methods of making, and using the same

Country Status (5)

Country Link
US (2) US8574590B2 (en)
EP (1) EP1660638B1 (en)
AU (1) AU2004286197A1 (en)
CA (1) CA2534236A1 (en)
WO (1) WO2005042695A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678539B2 (en) * 2000-08-10 2010-03-16 Corning Incorporated Arrays of biological membranes and methods and use thereof
US20070111201A1 (en) * 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
US20060223125A1 (en) * 2004-12-01 2006-10-05 Lelkes Peter I Methods and kits for staining cell membranes
US20070026426A1 (en) * 2005-04-26 2007-02-01 Applera Corporation System for genetic surveillance and analysis
WO2008020823A2 (en) * 2005-05-23 2008-02-21 University Of Hawaii Cooperative reporter systems, components, and methods for analyte detection
US8409263B2 (en) * 2005-08-05 2013-04-02 Gholam A. Peyman Methods to regulate polarization of excitable cells
US8465983B1 (en) * 2005-08-19 2013-06-18 Gabriel P. Lopez Detection and delivery systems utilizing supported lipid bilayers
US7518721B2 (en) * 2005-09-09 2009-04-14 Ge Homeland Protection, Inc. Raman-active lateral flow device and methods of detection
US8992511B2 (en) * 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8936590B2 (en) 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US9254256B2 (en) * 2005-11-09 2016-02-09 The Invention Science Fund I, Llc Remote controlled in vivo reaction method
US8882747B2 (en) 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US9028467B2 (en) * 2005-11-09 2015-05-12 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic pressure generation
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8377691B2 (en) * 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
EP2054087A2 (en) * 2006-07-06 2009-05-06 The Trustees of Columbia University in the City of New York Polychromatic, diversely-sized particles for angiography
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
CA2659275C (en) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
WO2008105918A2 (en) * 2006-08-18 2008-09-04 3M Innovative Properties Company Methods of detection using acousto-mechanical detection systems
US8168120B1 (en) 2007-03-06 2012-05-01 The Research Foundation Of State University Of New York Reliable switch that is triggered by the detection of a specific gas or substance
CA2703066A1 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
WO2009073523A2 (en) * 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
US9328172B2 (en) * 2008-04-05 2016-05-03 Single Cell Technology, Inc. Method of obtaining antibodies of interest and nucleotides encoding same
WO2009137242A2 (en) * 2008-04-14 2009-11-12 Michigan State University Trichoplusia ni cell line and methods of use
DE102008036064B4 (en) * 2008-06-17 2015-07-09 Jpk Instruments Ag A method and apparatus for determining cell activation of a target cell by an activator
WO2010030828A2 (en) * 2008-09-11 2010-03-18 University Of Maryland Biotechnology Institute Sonication-assisted metal-enhanced fluorescence (samef)-based bioassays
WO2010040023A2 (en) * 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
JP2012507565A (en) * 2008-10-30 2012-03-29 グオ・ペイシュエン Viral DNA packaging motor protein connector biosensor embedded in membrane for DNA sequencing and other applications
EP2356455B1 (en) * 2008-11-11 2015-03-04 Sanofi Pasteur VaxDesign Corporation Fluorescent neutralization and adherence inhibition assays
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
WO2010096414A2 (en) * 2009-02-17 2010-08-26 University Of Maryland Biotechnology Institute Metal-enhanced bioluminescence: an approach for monitoring biological bioluminescent processes
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
CN102753582A (en) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9499813B2 (en) * 2010-06-10 2016-11-22 President And Fellows Of Harvard College Systems and methods for amplification and phage display
US8900591B2 (en) 2010-08-20 2014-12-02 Heptares Therapeutics Limited Vaccines comprising mutant GPCRs with increased conformational stability relative to parent receptors
AU2011312562B2 (en) * 2010-09-27 2014-10-09 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
CN107190017A (en) * 2010-09-28 2017-09-22 圣母大学 Chimeric spider silk and application thereof
WO2012050896A2 (en) 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies
WO2012071012A2 (en) 2010-11-24 2012-05-31 National University Of Singapore Bodipy structure fluorescence dye for neural stem cell probe
WO2012104411A1 (en) * 2011-02-03 2012-08-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lipoproteins labelling, methods for tracking transport/outcome of lipoproteins and for determining dyslipidemia disorders
CN102951599B (en) * 2011-08-19 2015-11-18 中国科学技术大学 Micro-beam preparation method that antibody fragment is modified and micro-beam immune sensing detection system of modifying based on antibody fragment
JP2015527296A (en) 2012-03-26 2015-09-17 アメリカ合衆国 Novel delivery of packaged RNA to mammalian cells
JP6327662B2 (en) * 2012-09-26 2018-05-23 学校法人藤田学園 Method for measuring antibody using cell surface protein as antigen
US20140170727A1 (en) * 2012-12-19 2014-06-19 Nanomr, Inc. Affinity medium using fixed whole cells
WO2014121802A1 (en) * 2013-02-07 2014-08-14 Zaghloul Mohammad Hosam Eldeen Innovative nano-elisa single test for the detection of hcv, hiv antibodies and hbsag
EP3011061B1 (en) * 2013-06-21 2021-12-29 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins
EP3967325A1 (en) 2013-12-16 2022-03-16 The United States of America, as represented by The Secretary, Department of Health and Human Services Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
EP3221464B1 (en) * 2014-11-18 2022-02-23 The Trustees of Columbia University in the City of New York Detection of analytes using live cells
JP6367493B2 (en) * 2015-01-07 2018-08-01 インディー．インコーポレイテッド Method of mechanical and hydrodynamic microfluidic transfection and apparatus therefor
CN114478773A (en) 2015-01-09 2022-05-13 阿达尔塔有限公司 CXCR4 binding molecules
GB2535753A (en) * 2015-02-26 2016-08-31 The Native Antigen Company Particles comprising fusion proteins
EP3314255B1 (en) * 2015-06-25 2019-07-31 H. Hoffnabb-La Roche Ag Cell based assay for determining antibody or ligand binding and function
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
US10845305B1 (en) * 2015-11-20 2020-11-24 Verily Life Sciences Llc Method for increasing sensor resolution by spectrally stacking responsive dyes
US10663711B2 (en) 2017-01-04 2020-05-26 Corista, LLC Virtual slide stage (VSS) method for viewing whole slide images
JP6886854B2 (en) * 2017-04-13 2021-06-16 シスメックス株式会社 Information acquisition method for test substances
US20200400567A1 (en) * 2017-09-27 2020-12-24 Peking University Fusion polypeptide
JP6448826B1 (en) * 2018-01-17 2019-01-09 国立大学法人東京工業大学 Exosome production method and exosome obtained by the production method
CA3100642A1 (en) 2018-05-21 2019-11-28 Corista, LLC Multi-sample whole slide image processing in digital pathology via multi-resolution registration and machine learning
US11262309B2 (en) * 2018-07-11 2022-03-01 Advanced Cytometry Instrumentation Systems, Llc Methods for lipid measurement in cells
EP3864028A1 (en) * 2018-10-08 2021-08-18 Adolphe Merkle Institute, University of Fribourg Oligonucleotide-based tuning of pore-forming peptides for increasing pore size, membrane affinity, stability, and antimicrobial activity
EP3864159A4 (en) * 2018-10-09 2022-11-02 Nikegen Limited Compositions and methods for preparing viral vectors
CN111312411B (en) * 2018-12-11 2022-10-21 核工业西南物理研究院 Method for preventing plasma from cracking by injecting liquefied inert gas jet
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
CN113661175A (en) 2019-02-15 2021-11-16 整体分子公司 Antibodies comprising a common light chain and uses thereof
CN111983221B (en) * 2020-08-19 2024-04-09 深圳市卓润生物科技有限公司 Surface-modified magnetic bead and preparation method and application thereof
CN111983240B (en) * 2020-08-27 2023-11-21 天津大学 Visual detection method for clostridium perfringens alpha toxin
CN113608287B (en) * 2021-08-06 2023-06-02 暨南大学 Micro-lens and application thereof
WO2023172812A1 (en) * 2022-03-08 2023-09-14 Siemens Healthcare Diagnostics Inc. Liposome-containing diagnostic reagents and methods of production and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376236B1 (en) * 1993-09-15 2002-04-23 Chiron Corporation Recombinant alphavirus particles
US6583121B1 (en) * 1997-02-19 2003-06-24 University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
EP0871667A4 (en) 1994-11-18 1999-05-12 Human Genome Sciences Inc G-protein coupled receptor
US7763258B2 (en) * 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
JP2003504014A (en) 1999-06-30 2003-02-04 エボテック オーアーイー アクチェンゲゼルシャフト Viral particles, their preparation and preferably their use in pharmaceutical screening and functional genomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376236B1 (en) * 1993-09-15 2002-04-23 Chiron Corporation Recombinant alphavirus particles
US6583121B1 (en) * 1997-02-19 2003-06-24 University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALLIET J.W. ET AL.: "Efficient infection mediated by viral receptors incorporated into retroviral particles", J. VIROLOGY, vol. 72, no. 1, 1998, pages 671 - 676, XP002121047 *
ENDRES M.J. ET AL.: "Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes", SCIENCE, vol. 278, no. 5342, 21 November 1997 (1997-11-21), pages 1462 - 1464, XP002341005 *
HOFFMAN T.L. ET AL.: "A biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies and HIV-1 Env to chemokine receptors", PNAS, vol. 97, 2000, pages 11215 - 11220, XP003006201 *
OKIMOTO T. ET AL.: "VSV-G envelope glycoprotein forms complexes with plasmid DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA transfection", MOLECULAR THERAPY, vol. 4, no. 3, September 2001 (2001-09-01), pages 232 - 238, XP002990060 *
RICE J. ET AL.: "Inhibition of HIV-1 replication in alveolar macrophages by adenovirus gene transfer vectors", AM J RESPIR CELL MOL BIOL, vol. 27, no. 2, August 2002 (2002-08-01), pages 214 - 219, XP003006202 *
SHIVER J.W. ET AL.: "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", NATURE, vol. 415, no. 6869, January 2002 (2002-01-01), pages 331 - 335, XP002242910 *

Also Published As

Publication number Publication date
US9213027B2 (en) 2015-12-15
US8574590B2 (en) 2013-11-05
AU2004286197A1 (en) 2005-05-12
EP1660638B1 (en) 2015-12-23
EP1660638A4 (en) 2009-02-18
WO2005042695A2 (en) 2005-05-12
US20140135230A1 (en) 2014-05-15
EP1660638A2 (en) 2006-05-31
US20050123563A1 (en) 2005-06-09
CA2534236A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2005042695A3 (en) Lipoparticles comprising proteins, methods of making, and using the same
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2007035930A3 (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2006017538A3 (en) Hk1-binding proteins
WO2005092390A3 (en) Conjugates of hydroxyalkyl starch and a protein
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
EP1599228A4 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
AU2001273164A1 (en) Membrane associated protein zupari
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
AU2002312410A1 (en) Tissue-specific endothelial membrane proteins
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
GB0100513D0 (en) Process
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
WO2004094466A3 (en) Recombinant influenza viruses holding a mutation in a transmembrane protein gene
WO2009028625A1 (en) Method of binding protein to support using tamavidin
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2006076742A3 (en) Methods and compositions for increasing membrane permeability
WO2006029389A9 (en) Tryptophan-processing enzymes, nucleic acids encoding them and methods for making and using them
WO2008115296A3 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2534236

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004286197

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004816792

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004286197

Country of ref document: AU

Date of ref document: 20040730

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004286197

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004816792

Country of ref document: EP